GlassScriptPhysician profile
Olga Hardin
NPI 1477973568
$3,469.00
in general payments reported to CMS, 2019-2025
18 companies · $2,610 in 2025
The $2,610 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.85 · 2020: $492 · 2021: $37.02 · 2022: $148 · 2023: $26.56 · 2024: $138 · 2025: $2,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,774.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.51 | 2020-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $436.33 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $371.13 | 2024-2025 | |
| Glaxosmithkline, LLC. | $328.05 | 2020-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $303.88 | 2020-2025 | |
| Genentech USA, INC. | $268.65 | 2020-2025 | Xolair |
| Csl Behring | $252.90 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Ars Pharmaceuticals Operations, INC. | $159.53 | 2025 | Neffy |
| Pfizer INC. | $145.91 | 2020 | |
| Blueprint Medicines Corporation | $115.88 | 2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $113.40 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Grifols USA, LLC | $94.45 | 2021-2025 | Xembify |
| Amgen INC. | $67.29 | 2025 | Tezspire |
| Pharming Healthcare, INC. | $51.88 | 2025 | Ruconest |
| Lilly USA, LLC | $46.84 | 2025 | Ebglyss |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $23.75 | 2020 | |
| Alk-Abello, INC | $21.23 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Hardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.